Sublingual Diffusion of Epinephrine Microcrystals from Rapidly Disintegrating Tablets for the Potential First-Aid Treatment of Anaphylaxis: In Vitro and Ex Vivo Study
- 403 Downloads
For the first-aid treatment of anaphylaxis, epinephrine (Epi) 0.3 mg intramuscular (IM) injection in the thigh is the drug of choice. Epi auto-injectors are widely recommended for anaphylaxis treatment in community settings but not necessarily carried or used as prescribed when anaphylaxis occurs. We therefore developed rapidly disintegrating sublingual tablets (RDSTs) as an alternative noninvasive dosage form. Our objective in this study was to evaluate the effect of reducing Epi particle size on its in vitro and ex vivo diffusion, with the goal of enhancing Epi sublingual absorption from Epi RDSTs. Epi particle size was reduced by top-bottom technique using a microfluidizer for one pass at 30,000 Psi. The micronized Epi crystals (Epi-MC) were characterized using Zetasizer, Fourier transform infrared (FT-IR), differential scanning calorimetry (DSC), and scanning electron microscopy (SEM). Epi RDSTs were formulated and manufactured using our previously developed method. In vitro and ex vivo diffusion of Epi 10, 20, and 40 mg RDSTs and Epi-MC 10 and 20 mg RDSTs (n = 4) were evaluated using Franz cells. Epi 10 mg solution was used as a control. Mean (±standard deviation (SD)) Epi particle size was successfully reduced from 131.8 ± 10.5 to 2.5 ± 0.4 μm. Cumulative Epi diffused and influx from 40 mg Epi RDSTs and 20 mg Epi-MC RDSTs were not significantly different from each other in vitro and ex vivo (p > 0.05). Also, Epi permeability from 20 mg Epi-MC RDSTs was significantly higher than from the rest (p < 0.05). Epi-MC RDSTs improved Epi diffusion twofold and might have the potential to reduce the Epi dose needed in RDSTs by 50%.
KEY WORDSadrenaline anaphylaxis diffusion epinephrine sublingual
Dr. Rawas-Qalaji would like to acknowledge the financial support received from the President’s Faculty Research & Development Grant (PFRDG) at Nova Southeastern University. No financial or in-kind support for this study was provided by any corporate sponsor.
Conflict of Interest
Mutasem Rawas-Qalaji reports no declarations of interest.
Shima Werdy reports no declarations of interest.
Ousama Rachid reports no declarations of interest.
F. Estelle R. Simons reports no declarations of interest.
Keith J. Simons reports no declarations of interest.
- 8.Rawas-Qalaji MM, Simons FE, Simons KJ. Epinephrine for the treatment of anaphylaxis: do all 40 mg sublingual epinephrine tablet formulations with similar in vitro characteristics have the same bioavailability? Biopharm Drug Dispos. 2006;27(9):427–35. doi: 10.1002/bdd.519.CrossRefPubMedGoogle Scholar
- 11.Hoffman BB, Taylor P. Neurotransmission: the autonomic and somatic motor nervous systems. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill Companies, Inc; 2001. p. 115–53.Google Scholar
- 18.USP/NF. Physical tests: <905> uniformity of dosage units. United States Pharmacopeia 3. 37/32nd ed. Rockville: Pharmacopeial Convention, Inc; 2014. p. 491–4.Google Scholar
- 19.USP/NF. General chapters: <1216> tablet friability. United States Pharmacopeia 6. 37/32nd ed. Rockville: Pharmacopeial Convention, Inc; 2014. p. 1145–6.Google Scholar
- 20.USP/NF. Official monograph: epinephrine bitartrate. 31/26th ed. Rockville: United States Pharmacopeial Convention, Inc; 2008.Google Scholar
- 21.USP/NF. Official monograph: epinephrine injection. 31/26 ed. Rockville: United States Pharmacopeial Convention, Inc; 2008.Google Scholar